Drug Combination Boosts Treatment for Resistant Ovarian Cancer

by Madhumathi Palaniappan on  April 4, 2017 at 5:47 PM Health Watch
RSS Email Print This Page Comment bookmark
Font : A-A+

Highlights
  • Ovarian cancer is the sixth most common cancer in women.
  • A combination of drugs that include PARP inhibitor (Poly ADP ribose polymerase inhibitor) along with a kinase inhibitor has been found to treat ovarian cancer.
  • Olaparib (PARP inhibitor) along with a P13-kinase inhibitor drug is found to show a good duration response for 5.5 months.
Ovarian cancer patients who are less likely to respond to a PARP (Poly ADP ribose polymerase) inhibitor had a partial shrinkage in the tumor when a kinase inhibitor was added for treatment, finds a new study from the Dana-Farber Cancer Institute.
Drug Combination Boosts Treatment for Resistant Ovarian Cancer
Drug Combination Boosts Treatment for Resistant Ovarian Cancer

Panagiotis Konstantinopoulos, MD, Ph.D., said, "When we combined the two drugs, we obtained a very good response rate - as high as 36 percent in patients with ovarian cancer that was resistant to platinum-based chemotherapy."

The findings were presented during a clinical trials mini-symposium, at the annual meeting of the American Association for Cancer Research (AACR).

Research Study
The research study was conducted with twenty-eight patients who had high-grade serous ovarian cancer. Olaparib drug is a PARP inhibitor which is given along with an investigational alpha-specific P13-Kinase inhibitor, BYL719 in phase I trial.

Out of the 26 patients, 28 of them had platinum-resistant cancer. Konstantinopoulos, medical oncologist said, that such patients responded to a PARP inhibitor for as low as 4%

Pre-clinical studies showed that adding a P13K inhibitor may sensitize the cancer cells to the effects of the PARP inhibitor and may impair the ability of tumor cells to repair the DNA damage.

Study Findings
The findings of the study showed that the median duration of the response in the ovarian cancer patients was about 5.5 months.

Konstantinopoulos, said, that 5.5months would be a good duration of response in the patient population. Five patients were found to be remaining on treatment at the time of presentation.

Four of the 28 patients discontinued the therapy due to toxicity.

Olaparib Drug
The drug is approved for treating platinum-resistant ovarian cancer in women with germline breast cancer gene mutation. The drug mainly acts by killing the cancer cells.

Side effects
  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Breathing difficulties
  • Sleep disturbances
  • Weakness
  • Pale skin
In the present trial, the response rate may be 29% in women without germline BRCA (Breast cancer gene mutations). This was not much lower than the rate of 33% in patients who were without the inherited BRCA mutations.

Konstantinopoulos said, "The activity of this combination in ovarian cancer patients without germline BRCA mutations and with platinum-resistant disease was higher than expected from olaparib monotherapy and warrants further investigation."

References
  1. Olaparib - ( https:medlineplus.gov/druginfo/meds/a614060.html)


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Ovarian Cancer Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Drugs Banned in India Meigs Syndrome Ovarian Pain 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive